[Thalidomide combined with interferon and interleukin-2 in treatment of relapsed or refractory acute myelogenous leukemia].

Wei, X D; Ai, H; Mi, R H; Chen, L; Yuan, F F; Hao, Q M; Yin, Q S; Wang, P; Song, Y P

Wei, X D; Ai, H; Mi, R H; Chen, L; Yuan, F F; Hao, Q M; Yin, Q S; Wang, P; Song, Y P.

Affiliation

Wei XD; Department of Hematology, Henan Tumor Hospital, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, China.

Zhonghua Nei Ke Za Zhi ; 55(11): 875-877, 2016 Nov 01.

Article in Zh | MEDLINE | ID: mdl-27801345

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Interferons/therapeutic use; Interleukin-2/therapeutic use; Leukemia, Myeloid, Acute/drug therapy; Thalidomide/therapeutic use; Adult; Antineoplastic Agents/therapeutic use; Female; Humans; Interferons/administration & dosage; Interleukin-2/administration & dosage; Male; Middle Aged; Recurrence; Remission Induction; Thalidomide/administration & dosage; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Thalidomide / Leukemia, Myeloid, Acute / Antineoplastic Combined Chemotherapy Protocols / Interferons / Interleukin-2 Limits: Adult / Female / Humans / Male / Middle aged Language: Zh Year: 2016 Type: Article

Fulltext

XML

PubMed Links

Search on Google